Inclusion and Exclusion Criteria
The eligibility criteria included(1)be a phase 2 or 3 clinical randomized controlled trials (RCTs) for trunk and limbs of adults plaque psoriasis and have at least 50 participants in each study;(2) topical interventions included were:tofacitinib, tapinarof, benvitimod, calcipotriol, roflumilast, Cal/BD, betamethasone, tacalcitol, halobetasol,HP/TAZ and vehicle(placebo);(3)studies reporting at least one of efficacy outcomes(PGA0/1,IGA0/1,PASI75) and safety outcomes (AEs,AEs leading to discontinuation of trial), all outcomes were extracted at 4–12weeks.The exclusion criteria included case reports, letters,retrospective studies, researches without data in outcomes and lack usable date.